BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260516T004108
CREATED:20231120T110619Z
LAST-MODIFIED:20231120T110619Z
UID:38173-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:6th Annual CRISPR AgBio Congress
DESCRIPTION:The 6th Annual CRISPR AgBio Congress is back on February 20-22\, 2024 (Raleigh\, NC). The dedicated congress that unites industry stakeholders across Agbiotech\, big seed\, distributors\, and investors\, to assess this new regulatory terrain\, examine recent scientific breakthroughs\, and strategize the journey of CRISPR products from editing to delivery\, field to shelf. \nDiscover the full program here. \nBack for its 6th edition\, join the likes of the Pairwise CEO\, and advisors at USDA and EPA as we: \n\nDiscover the latest on the global and US regulatory landscape\, uncover what’s new for standardizing approval processes\, and tackle regulatory compliance for your products\nUncover novel gene editing tools and CRISPR technologies\, AI\, Cas-12\, and CRISPR-enabled breeding and trait discovery tools to address unmet agricultural challenges\nExplore CRISPR product commercialization and effective market targeting strategies for rapid adoption\nTransform agriculture with sustainable crop solutions: explore alternative fuels and precision breeding for enhanced crop sustainability\nUnpick how to enhance the adaptability\, productivity\, and nutrition of orphan and non-model crops such as potatoes\, and strawberries to accelerate breeding and cut costs\n\nView your copy here to find the jam-packed agenda\, with exclusive case studies led by industry giants and regulatory bodies to help you commercialize regulatory-approved gene-edited agriculture products. \nJoin 80+ C-level leaders\, researcher heads\, Molecular Biologists\, Regulatory Experts\, and Product Developers from major seed companies\, innovative Agbiotechs\, influential academic institutions\, and regulatory bodies and be part of the conversation in 2024. \nHere’s what past attendees had to say: \n“Great quality of presentations and coherent style of participants: scientists with key roles in their company and key relevant academic researchers” – Chief Executive Officer\, Meiogenx   \n“The arrangements for the conference\, quality of speakers\, and novel ways to encourage networking were great” – Senior Director\, Yield10 Bioscience
URL:http://www.pharmajournalist.com/event/6th-annual-crispr-agbio-congress/
LOCATION:Sheraton Raleigh Hotel\, 421 South Salisbury St\, Raleigh\, NC\, 27601\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.con
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260516T004108
CREATED:20240103T113819Z
LAST-MODIFIED:20240103T113819Z
UID:38417-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:2nd Viral Vector Process Development & Manufacturing
DESCRIPTION:Viral Vector Process Development & Manufacturing Summit\nCreate Qualitative\, Accessible Treatments for Patients \nFollowing Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities\, and BMS’s viral vector facility coming online\, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies. \n \nWith the FDA’s fast-evolving quality assessment and lack of standard guidance\, and the continued challenge of viral vector recovery yield and purity\, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations. \nIn collaboration with Sarepta\, Ultragenyx\, Affinia Therapeutics\, and UCB\, we will unite 130+ pioneering viral vector up- and downstream process engineers\, MSAT\, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up\, tech transfer\, and speed-to-clinic. Returning to Boston in February\, we are proud to expand the program into 2 tracks of content as the only industry-led\, end-to-end summit to align with your needs: \n\nDownstream process intensification\, including purification\, to improve recovery and yield\nPurity assessment to uphold GMP and product quality assessment\nDeep dive into upstream process development and cell line in relation to your viral vectors\, and assess platforming strategy\nRapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs\nMeet and evaluate solution providers and viral vector CDMOs\, including Lonza\, Chromatan\, Teknova\, and Genezen\, to forge long-term relationships\, ensuring tech transfer readiness\n\nIt’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing! \nTo know more visit: https://ter.li/fvlk3e
URL:http://www.pharmajournalist.com/event/2nd-viral-vector-process-development-manufacturing/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR